Codexis, Inc.

Welcome to the Cadexis fourth quarter and full year 2024 earnings conference call. At this time, all participants are in a listen-only mode. A question and answer session will follow the formal presentation. If anyone should require operator assistance, please press star zero on your telephone keypad. Please note that this event is being recorded. And now I'll turn the call over to Carrie McKim, Director of Investor Relations. Please go ahead.

Thank you, Operator. With me today are Dr. Stephen Dilley, Codex's President and Chief Executive Officer, Kevin Norritt, Chief Operating Officer, and Georgia Herbez, Chief Financial Officer. During this call, management will be making a number of forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995, including our guidance for 2025 revenue, anticipated milestones, including product launches, pilot scale manufacturing, and paths to scale up technical milestones, and public announcements related thereto, as well as our strategies and prospects for revenue growth, path to profitability, and successful execution of current and future programs and partnerships. To the extent that statements contained in this call are not descriptions of historical facts regarding Codexys, they are forward-looking statements reflecting the beliefs and expectations of management as of the statement date, February 27, 2025. You should not place undue reliance on these forward-looking statements because they involve known and unknown risk uncertainties, and other factors that are, in some cases, beyond Codexys control and that could materially affect actual results. Additional information about factors that could materially affect actual results can be found in Codexys filings with the Securities and Exchange Commission. Codexys expressly disclaims any intent or obligation to update these forward-looking statements, except as required by law. And now, I'll turn the call over to Stephen.

Thank you, Carrie, and thanks, everyone, for joining. I'm very pleased with the progress we've made over the last year. Firstly, we've worked hard to return our heritage pharma manufacturing business to a healthy growth trajectory. Secondly, we've made significant progress in reducing costs, strengthening our balance sheet, and defining a path to profitability. This really sets the stage for us to realize the intrinsic value in our enzymatic oligonucleotide synthesis capability, beginning with the EcoSynthesis platform. Moving to slide three, it's remarkable that in just two short years, we've moved enzymatic siRNA synthesis from an exciting idea to a near-term reality. As you may recall, we presented some important data at the TIDES Europe meeting last November. First, we showcased the remarkable capabilities of our engineered RNA ligase enzymes that can increase the efficiency of conventional chemical siRNA synthesis. We demonstrated the broad potential utility of our ecosynthesis platform by successfully synthesizing in Clizaran, a commercially approved siRNA drug, by four different methods, ranging from enzymatic ligation of chemical fragments to the first ever end-to-end enzymatic synthesis of the entire molecule. We've essentially built a toolbox that allows us to partner with innovative companies to determine the best option to build their particular siRNA molecule. Our presentations at TIDES were very well received by our industry colleagues, and we saw a noticeable increase in customer engagement, both for the RNA ligase and full-ecosynthesis platforms. We've successfully completed feasibility studies with multiple leading siRNA innovator companies, and with the recent completion of our EcoInnovation Lab, we're now ready to move forward into signing and executing revenue-generating contracts with development work expected to start in early Q2. 2025 is slated to be the year we achieve commercial liftoff for the Ecosynthesis platform. To walk you through how we get there, let me turn it over to Kevin.